Li Qin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Li Qin has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Deqiao Qin
Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
1 shared publication - Jingjiao Song
Huazhong University of Science and Technology
1 shared publication - Lijuan Wu
Department of Dermatology, Traditional Chinese and Western Medicine Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
1 shared publication - Lingli Dong
Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
1 shared publication - Rongfen Gao
Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030 Wuhan, China
1 shared publication Tingwen Xie
Department of Dermatology, Traditional Chinese and Western Medicine Hospital of Wuhan, Tongji Medical college, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China; Department of Dermatology, Wuhan No.1 Hospital, Wuhan, Hubei 430022, China; Hubei Province & Key Laboratory of Skin Infection and Immunity, Wuhan, Hubei 430022, China
1 shared publication
Latest Publications
- 7 June 2026
- Published by Elsevier in Microbiological Research
- Vol. 311, 128577
The skin microbiome as a key regulator of psoriasis: From dysbiotic drivers to host-directed therapeutics
- 7 June 2026
- Published by Elsevier in Microbiological Research
- Vol. 311, 128577
The skin microbiome as a key regulator of psoriasis: From dysbiotic drivers to host-directed therapeutics
- Open Access
- 26 November 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (12) , 1802
Myricetin Attenuates IMQ-Induced Psoriatic Inflammation Through Multi-Target Modulation: Evidence from Network Pharmacology and Experimental Validation
Background: Psoriasis is a chronic inflammatory skin disease driven by keratinocyte hyperproliferation and immune dysregulation. Despite the availability of biologics and immunosuppressants, recurrence and adverse effects remain major limitations. Myricetin (Myr), a natural flavonoid with well-documented anti-inflammatory and immunomodulatory properties, has shown promise in inflammatory disorders; however, its efficacy and mechanisms in psoriasis have not been fully elucidated. Methods: The therapeutic effects of topical Myr (0.5–2%) were evaluated in an imiquimod (IMQ)-induced psoriatic mouse model. Network pharmacology and molecular docking were employed to predict potential targets, followed by validation using histological analysis, cytokine profiling, qPCR, and Western blotting. Results: Network analysis identified 52 overlapping targets between Myr and psoriasis, including TNF, PTGS2, MMP9, and EGFR, with enrichment in TNF, IL-17, and PI3K/AKT signaling pathways. Myr treatment significantly alleviated IMQ-induced erythema, scaling, and epidermal thickening, improved skin-barrier function, and reduced the expression of IL-6, IL-17A, and TNF-α. Molecular docking showed strong binding affinities of Myr with TNF, PTGS2, MMP9, and EGFR. Western blotting confirmed that Myr suppressed EGFR and AKT phosphorylation and downregulated Mmp9, Ptgs2, and Tnf expression. Conclusions: Myr exerts multi-target anti-psoriatic effects by inhibiting the EGFR/AKT axis and inflammatory mediators, highlighting its potential as a safe and effective natural therapeutic agent for psoriasis.
- 26 November 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (12) , 1802
Open AccessMyricetin Attenuates IMQ-Induced Psoriatic Inflammation Through Multi-Target Modulation: Evidence from Network Pharmacology and Experimental Validation
Background: Psoriasis is a chronic inflammatory skin disease driven by keratinocyte hyperproliferation and immune dysregulation. Despite the availability of biologics and immunosuppressants, recurrence and adverse effects remain major limitations. Myricetin (Myr), a natural flavonoid with well-documented anti-inflammatory and immunomodulatory properties, has shown promise in inflammatory disorders; however, its efficacy and mechanisms in psoriasis have not been fully elucidated. Methods: The therapeutic effects of topical Myr (0.5–2%) were evaluated in an imiquimod (IMQ)-induced psoriatic mouse model. Network pharmacology and molecular docking were employed to predict potential targets, followed by validation using histological analysis, cytokine profiling, qPCR, and Western blotting. Results: Network analysis identified 52 overlapping targets between Myr and psoriasis, including TNF, PTGS2, MMP9, and EGFR, with enrichment in TNF, IL-17, and PI3K/AKT signaling pathways. Myr treatment significantly alleviated IMQ-induced erythema, scaling, and epidermal thickening, improved skin-barrier function, and reduced the expression of IL-6, IL-17A, and TNF-α. Molecular docking showed strong binding affinities of Myr with TNF, PTGS2, MMP9, and EGFR. Western blotting confirmed that Myr suppressed EGFR and AKT phosphorylation and downregulated Mmp9, Ptgs2, and Tnf expression. Conclusions: Myr exerts multi-target anti-psoriatic effects by inhibiting the EGFR/AKT axis and inflammatory mediators, highlighting its potential as a safe and effective natural therapeutic agent for psoriasis.